| Literature DB >> 29880480 |
Marjan Rafat1, Todd A Aguilera2, Marta Vilalta1, Laura L Bronsart1, Luis A Soto1, Rie von Eyben1, Meghana A Golla1, Yasaman Ahrari1, Stavros Melemenidis1, Anosheh Afghahi3, Melissa J Jenkins1, Allison W Kurian3, Kathleen C Horst1, Amato J Giaccia1, Edward E Graves4.
Abstract
Although radiotherapy (RT) decreases the incidence of locoregional recurrence in breast cancer, patients with triple-negative breast cancer (TNBC) have increased risk of local recurrence following breast-conserving therapy. The relationship between RT and local recurrence is unknown. Here, we tested the hypothesis that recurrence in some instances is due to the attraction of circulating tumor cells to irradiated tissues. To evaluate the effect of absolute lymphocyte count on local recurrence after RT in patients with TNBC, we analyzed radiation effects on tumor and immune cell recruitment to tissues in an orthotopic breast cancer model. Recurrent patients exhibited a prolonged low absolute lymphocyte count when compared with nonrecurrent patients following RT. Recruitment of tumor cells to irradiated normal tissues was enhanced in the absence of CD8+ T cells. Macrophages (CD11b+F480+) preceded tumor cell infiltration and were recruited to tissues following RT. Tumor cell recruitment was mitigated by inhibiting macrophage infiltration using maraviroc, an FDA-approved CCR5 receptor antagonist. Our work poses the intriguing possibility that excessive macrophage infiltration in the absence of lymphocytes promotes local recurrence after RT. This combination thus defines a high-risk group of patients with TNBC.Significance: This study establishes the importance of macrophages in driving tumor cell recruitment to sites of local radiation therapy and suggests that this mechanism contributes to local recurrence in women with TNBC that are also immunosuppressed.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/15/4241/F1.large.jpg Cancer Res; 78(15); 4241-52. ©2018 AACR. ©2018 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29880480 PMCID: PMC6072588 DOI: 10.1158/0008-5472.CAN-17-3623
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 13.312